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 Introduction 
 Since many eye diseases are age-related, current in-
creases in life expectancy are bound to have a major in-
fluence on the epidemiological profile of reduced vision 
and blindness in highly developed European countries. 
Currently, it is estimated that 45 million persons world-
wide are blind, with an increase of 1–2 million each year 
 [1] . 
 Age-related macular degeneration (AMD) (26%), glau-
coma (20.5%) and diabetic retinopathy (8.9%) are the 
most frequent causes of blindness in Europe  [2] . Public 
health efforts should focus on the above-mentioned con-
ditions, as they represent the most frequently reported 
causes of visual disability in Europe and can be prevented 
or cured through proved cost-effective interventions. In 
other words, they represent the major causes of avoidable 
blindness and visual impairment  [2] . Reliable European 
epidemiological data are needed for planning of preven-
tion and intervention strategies tackling these economi-
cally relevant diseases.
 Many epidemiological studies on age-related eye dis-
orders have been carried out in the USA  [3–11] . On the 
other hand, only few literature reviews on this question 
have been published in Europe. As a result, European 
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 Abstract 
 The objective of this work was to study the epidemiology of 
major eye diseases leading to blindness in Europe through a 
systematic literature review. The literature search was per-
formed using the Medline database (PubMed), with MeSH 
and free text search terms. Inclusion criteria for the studies 
were: (a) performed on a healthy population of Caucasian 
origin aged between 50 and 75 years; (b) diagnosed by oph-
thalmological examination in accordance with the  Interna-
tional Classification of Diseases 10 ; (c) contained a detailed de-
scription of the sampling and diagnostic procedures and 
data resources; (d) sample size  1 500, and (e) published be-
tween 1990 and 2008. The results of 57 studies on the preva-
lence and incidence of age-related macular degeneration, 
diabetic retinopathy and glaucoma are reported, providing 
an up-to-date and comprehensive overview of these diseas-
es in Europe from an epidemiological perspective. 
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health services and research policies still lack the myriad 
benefits of such collated information. 
 Moreover, existing studies focus for the most part only 
on a single eye disorder, such as AMD  [12–14] , diabetic 
retinopathy  [15–17] , glaucoma  [18, 19] or cataract  [20, 21] . 
Despite the high value of the data from these studies, 
there is still a pressing need for a complete picture of the 
epidemiological status of age-related eye diseases in Eu-
rope. 
 The present study therefore undertook to describe the 
present status of epidemiological research on the preva-
lence and incidence of major eye diseases leading to 
blindness in Europe through a systematic literature re-
view. The aim was to identify the individual impact of 
each eye disorder in relation to age and to compare the 
results among different European countries.
 Search Strategy and Selection Criteria 
 A literature search was performed in the Medline database 
(PubMed), using the controlled vocabulary (MeSH) search terms 
‘AMD/epidemiology’[Mesh], ‘AMD/statistics and numerical 
data’[Mesh], ‘Glaucoma/epidemiology’[Mesh] and ‘Glaucoma/
statistics and numerical data’[Mesh], ‘Diabetic retinopathy/
epidemiology’[Mesh], ‘Diabetic retinopathy/statistics and nu-
merical data’[Mesh], and the free text search terms ‘AMD’, ‘dia-
betic retinopathy’, ‘glaucoma’, ‘high intraocular pressure’, ‘ocular 
hypertension’, ‘prevalence’, ‘incidence’, ‘population-based’, ‘cross-
sectional’, ‘longitudinal cohort studies’, ‘epidemiology’ and ‘sta-
tistical data’. 
 Only those studies were included which: (a) were carried out 
in a generally healthy population of Caucasian origin aged 50 and 
older, (b) were based on diagnoses made by ophthalmological ex-
amination in accordance with  International Classification of Dis-
eases ; (c) included a detailed description of sampling and diagnos-
tic procedures as well as data resources; (d) involved a sample size 
 1 500, and (e) were published between January 1990 and Decem-
ber 2008. 
 Articles written in English, Spanish, German, Russian, and 
French were assessed. Only studies using standardized proce-
dures for disease diagnosis were included. The abstracts of the 
articles identified were reviewed and those considered of high and 
medium relevance were obtained. Additionally, attention was 
also given to articles referenced in the selected articles. Special at-
tention was given to studies focusing on prevalence and incidence 
by age and gender. Prevalence quantifies the proportion of indi-
viduals in a population who have a disease at a specific instant. 
Incidence quantifies the number of new events or cases of the dis-
ease that develop in a population of individuals at risk during a 
specific time interval. The results will be shown here via colour-
coded maps of Europe for crude incidence and prevalence values 
and in tables for age- and sex-specific indicators. Clinical out-
comes, risk factors, disease progression, the socio-economic im-
pact on blindness caused by major eye diseases, and the most ef-
fective treatment strategies were noted and will be discussed here. 
 Results 
 The present study reviewed, to the best of the authors’ 
knowledge, all relevant European studies on the epidemi-
ology of major eye diseases. Fifty-seven studies published 
from 1990 to 2008 met the inclusion criteria: 13 European 
studies on AMD (4 multicentre studies  [13, 22–24] , 6 
prevalence studies from the Netherlands  [25] , Germany 
 [26] , France  [27] , the UK  [28] , the European North of Rus-
sia  [29] and Bulgaria  [2] , and 3 incidence studies from 
Rotterdam  [22, 30] and Germany  [31] ), 23 studies of dia-
betic retinopathy (1 global  [32] , 3 European  [33–35] ; 2 
multicentre European  [15, 36, 37] and 2 multicentre from 
Spain  [38] and Germany  [26, 39] , 1 long-term follow-up 
study from Germany  [40] ; 7 population-based studies  [2, 
30, 31, 41–45] , 5 cross-sectional studies from Germany 
 [39] , France  [46] , Europe  [27, 37] , Spain  [47] and 2 litera-
ture reviews  [16, 35] ), 5 studies of ocular hypertension, 
including 4 cross-sectional studies: 1 from Spain  [48] , 2 
from France  [49, 50] , 1 cross-sectional study of high in-
traocular pressure  [51] , and 1 longitudinal study from 
Austria  [52] ; 17 glaucoma studies including 2 prospective 
longitudinal studies from the UK  [53, 54] , 6 population-
based studies: 1 from Bulgaria  [2] , 1 from the European 
North of Russia  [29, 36] , 1 from Italy  [2] , 3 from the Neth-
erlands  [1, 2, 45] , 4 cross-sectional studies: 2 from Russia 
 [55, 56] , 1 from France  [46, 49] and 1 from Spain  [48] and 
4 incidence studies: 1 from the European North of Russia 
 [56] , 2 from Germany  [31, 57] , and 1 from the UK  [54] . 
The data on prevalence will be reported here in percent, 
with 95 or 99% confidence intervals (CIs); incidence will 
be presented in percent or in the number of cases per 
population size or person-years. 
 Epidemiology of AMD 
 AMD is the most common cause of severe vision loss 
worldwide and is characterized by the loss of central vi-
sion. Blindness due to AMD occurs at advanced age; over 
80% of those affected become blind after 70 years of age 
 [58] . AMD has two forms: ‘wet’ (i.e. neovascular and exu-
dative) AMD and ‘dry’ AMD. Dry AMD tends to progress 
more slowly than wet AMD  [22] . The prevalence of AMD 
in individuals aged 65–75 ranged between 9 and 25%  [22] . 
It is higher in women [1.03% (95% CI: 0.11–1.96)] than in 
men [0.90% (95% CI: 0–2.08)] at 65–69 years of age, and 
changes with age, with a greater increase in women from 
1.03% (95% CI: 0.11–1.96) at 65–69 years of age to 2.36% 
(95% CI: 1.00–3.73) at 70–74 years of age  [13] . The propor-
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tion of visual impairment due to AMD has been found to 
vary between 40% in France  [27] , 39% in Germany  [26] , 
36.3% in the Netherlands  [25] , 16.30% in the European 
North of Russia  [29] , and 14% in Bulgaria  [2] . A pooled 
estimate of AMD prevalence showed that 3.5% (95% CI: 
3.0–4.1) of individuals 75 years or older in the UK had 
AMD  [28] . The incidence rate of AMD increased with age 
from 0 (95% CI: 0–1.0) for the age group 55–64, 0.75 (95% 
CI: 0.15–2.2) for the age group 65–74 and 3.07 (95% CI: 
1.1–6.7) for the population between 74 and 84 years of age 
 [30] . Owen et al.  [28] estimated that there are 172,000 in-
dividuals (95% CI: 106,000–279,000) with geographic 
AMD and 245,000 (95% CI: 163,000–364,000) with neo-
vascular AMD in the UK. This study showed that neovas-
cular AMD is the more common cause of blindness reg-
istration and leads to more rapid visual loss in comparison 
to geographic AMD  [28] . Importantly, this study also un-
derlines that patients with geographic AMD tend to pres-
ent at the eye hospital at early disease stages whereas those 
with neovascular AMD are more likely to present acutely 
at late disease stages. This should be taken in consider-
ation when comparing the prevalence and incidence of 
these AMD subtypes. 
 The studies discussed here are different in design: a 
study by Owen et al.  [28] is a systematic review with sub-
sequent use of the pooled data for the UK, whereas a study 
by Cohen et al.  [27] is a hospital-based prospective study, 
which was undertaken in a semi-rural area of France. On 
the other hand, a Rotterdam population-based cohort 
study on individuals of 55 years of age and older reports 
36.3% patients with AMD at a baseline  [25] . All of these 
studies used different age group definition criteria and 
had different study designs and settings, which makes 
direct comparison of their results problematic. 
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 Fig. 1. Prevalence of AMD in Europe ac-
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 A population-based prospective cohort study with a 
follow-up period of 6.5 years and a total number of 6,418 
participants performed in Rotterdam showed that the 
crude incidence rate of AMD in men was 2.0 per 1,000 
person-years and 1.6 per 1,000 person-years in women; 
this difference was not significant when corrected for age 
[rate ratio, 0.7 (95% CI: 0.4–1.2) (women vs. men)]  [22] . 
The most recent population-based study in Germany in-
dicated that the incidence of blindness due to AMD in 
Germany is 3.93 per 100,000  [31] .  Figure 1 shows a map 
of the overall prevalence of AMD in Europe.  Figure 2 
shows the incidence of AMD in Europe. Data on the prev-
alence and incidence of AMD by age and gender are 
shown in  table 1 . Age- and sex-specific prevalence of dif-
ferent AMD types is listed in  table 2 . 
 Clinical Outcomes and Socio-Economic Impact of 
AMD 
 Clinical Outcomes 
 AMD is the leading cause of severe visual loss in per-
sons older than 65 years  [49, 59] . Overall, 25–30 million 
individuals worldwide have severe visual loss due to 
AMD  [60] . Neovascular (exudative or wet) AMD repre-
sents 10–15% of all cases of AMD and accounts for more 
than 90% of severe visual loss due to AMD. Patients with 
bilateral neovascular AMD report a substantially lower 
quality of life, poorer vision-related functioning, greater 
anxiety and depression, more frequent falls and frac-
tures, and greater dependency on caregivers. From a clin-
ical perspective, the adverse effects of AMD are a reduc-
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Table 1. P revalence and incidence of AMD by age and gender in the reviewed studies
Study name/
country
Design Sample
size
Study year/
follow-up 
period
Age
groups
Gender Prevalence Incidence Remarks Ref. 
No.
Eureye
(European
Eye Study)
multicenter
population-based
cross-sectional
4,753 2006 65–69 male 0.90 (0–2.08) SQ and 
OPHTH
13
70–74 male 1.97 (0.77–3.17)
female 2.36 (1.00–3.73)
>65 both 3.3 (2.5–4.1)
Thessaloniki
Eye Study, 
Greece
cross-sectional
population-based
2,554 2006 60–64 male 0.62% OPHTH 13
female 0.67%
65–69 male 0.82%
female 1.23%
70–74 male 2.06%
female 1.96%
75–79 male 2.78%
female 3.54%
>80 male 10.95%
female 8.75%
UK literature
review study
98,757 2001 65–79 male 0.15 (0.03–0.27) 28
female 0.21 (0.09–0.33)
both 0.35 (0.14–0.57)
Germany retrospective
longitudinal study
3,531 1994–1998 60–79 both 6.10 (5.39–6.80) OPHTH 59
Rotterdam, 
Netherlands
population-based
prospective cohort 
study
6,418 2003/
6.5 years
66–69 both 10.8 (8.6–13.7) SQ, FI, 
OPHTH
 
22
70–74 both 19 (15.6–23.2)
male 2 per 1,000 person-years
female 1.6 per 1,000 person-years
Th e grading of AMD is based on an international classification and grading system for AMD and ARMD. SQ = Standard questionnaire; FI = fundus 
image; OPTH = ophthalmological examination.
Table 2.  Age- and sex-specific prevalence of AMD types
Type of AMD Study
location
Study design Sample
size
Year Age
group
Gender Prevalence Method of
diagnosis
Ref. 
No.
Geographic AMD UK literature review
(27 references)
98,757 2001 65–79 both 0.53 (0.37–0.68) OPHTH 28
Neovascular AMD 65–79 both 1.05 (0.57–1.52)
Geographic AMD 65–79 male 0.60 (0.35–0.85)
female 0.45 (0.26–0.64)
Neovascular AMD 65–79 male 0.81 (0.52–1.11)
female 1.03 (0.49–1.58)
Early AMD Europe multinational cross-
sectional study
not
indicated
2008 65–74 both 15% OPHTH 14
Late AMD 1%
Any AMD Rotterdam, 
Netherlands
prospective
follow-up study
6,781 1990–1993 65–74 both 10% FIG, OPHTH 4
Early AMD 55–64 2.4%
Late AMD 65–74 9.2%
T he grading of AMD is based on an international classification and grading system for AMD and ARMD.
FIG = Fundus image grading; OPHTH = ophthalmological examination.
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tion in visual acuity, contrast sensitivity and the develop-
ment of central scotoma  [61, 62] . 
 Natural Progression of AMD 
 A study of the natural progression of untreated age-
related macular degeneration showed that the median 
time between referral assessment and treatment is 28 
days (interquartile range = 36.5 days); 44% of the inves-
tigated subjects had some degree of visual loss and 16% 
lost more than 3 lines of distance visual acuity  [63] . The 
time between initial diagnosis and treatment correlated 
with the progression of visual loss (r = 0.50, p = 0.003) 
 [63] . Average time from baseline to initial appearance of 
geographic atrophy is 6.6 years (range 4–11). Time from 
lesion appearance to onset of geographic atrophy de-
pends on the lesion type and ranges from 2.5 to 5.9 years 
 [64] .
 Economic Costs 
 AMD results in a substantial economic burden. Cruess 
et al.  [64] performed a multicountry observational study 
of the economic burden of bilateral neovascular AMD. 
Societal costs including direct vision-related medical 
costs (e.g. treatment of AMD and vision-related equip-
ment), direct non-vision-related medical costs (e.g. med-
ications) and direct non-medical-related costs (e.g. home 
healthcare and social services) were measured in this 
study. In 2005, the annual societal cost per bilateral neo-
vascular AMD varied by country: 7,349 EUR in France, 
12,445 EUR in Germany, 5,732 EUR in Spain and 5,300 
EUR in the UK  [64] . Direct vision-related medical costs 
accounted for 23–63% of the total costs  [64] . Limited re-
search has been done on the economic burden of neovas-
cular and geographic AMD in Europe. Results of a retro-
spective, observational, population-based study based on 
Medicare data showed that median eye-related Medicare 
costs were USD 1,607 for neovascular AMD patients, 
USD 832 for non-neovascular/dry AMD patients, and 
USD 658 for controls  [65] . 
 Such a high economic burden highlights both the im-
portance of early AMD screening and the development 
of new therapies that slow disease progression  [66] . Treat-
ment interventions, such as ranibizumab therapy, laser 
photocoagulation, pegaptanib (macugen) therapy, and 
photodynamic therapy (PDT) have been shown to im-
prove quality of life, with the highest increase for ranibi-
zumab therapy  [67] . An overview of a broad range of cost-
effectiveness analyses showed that ranibizumab was the 
most cost-effective therapy for wet AMD in comparison 
with other approved therapies (e.g. vs. PDT or pegap-
tanib). Pegabtanib was found to be cost-effective com-
pared to usual/best supportive care (including PDT) or 
no treatment only when treatment was initiated in early 
or moderate stages of disease  [68] . PDT was found most 
likely to be cost-effective when prescribed early to pa-
tients with better visual acuity  [69] . Laser photocoagula-
tion was also shown to be a cost-effective treatment op-
tion for wet AMD treatment. Costs per quality-adjusted 
life-year (QALY) gained for laser treatment compared to 
no treatment or observation were USD 5,629–23,176 over 
a time frame of 11–14 years  [70–72] . A Novartis-spon-
sored literature review underlines that there are no reli-
able studies on cost-effectiveness of bevacizumab; there-
fore, off-label use of this treatment strategy is controver-
sial  [73] . Additionally, it reports a lack of safety data and 
little evidence from robust randomized control trials, 
preventing the proper assessment of the cost-effective-
ness of bavacizumab in wet AMD  [73] . Most importantly, 
the pharmacokinetics and pharmacodynamics of bevaci-
zumab are different from those of ranibizumab. Mitchell 
et al.  [73] stress that further robust randomized clinical 
trials (RCTs) are needed to establish the safety and clini-
cal effectiveness of AMD treatment with bevacizumab. 
Clinical trials on the efficacy of nutrition components in 
reducing AMD progression and its prevention are ongo-
ing  [74] . 
 Epidemiology of Diabetic Retinopathy in Europe 
 Diabetic retinopathy is one of the most sight-threat-
ening complications of diabetes mellitus and one of the 
most important emerging causes of blindness. It ac-
counts for about 2.4 million cases of blindness globally 
 [75] . A proportion of 4.8% of the global population has 
diabetic retinopathy  [32] , while 3  [32] to 4.1%  [33] of Eu-
ropeans are affected. According to recent epidemiologi-
cal data, the prevalence of diabetic retinopathy in indi-
viduals over 60 years of age is the highest in France 
(16.6%)  [46] , followed by Germany (10.6%)  [39] . A pro-
spective multinational WHO cohort study that included 
4,662 adult participants who were followed up over a pe-
riod of 8.4 years showed that the incidence of any dia-
betic retinopathy in patients with type II diabetes was 
the highest in the UK (43.3%), followed by Switzerland 
(42.3%), Poland (31.8%), and Germany (29.9%)  [34] . A 
population-based survey performed in Germany showed 
that 60- to 74-year-old men had a higher incidence of 
diabetic retinopathy (29%) than women in the same age 
range (16.51%)  [31] . Mild to moderate diabetic retinopa-
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thy (8.5%) was the most prevalent in Germany followed 
by non-proliferative (1.7%) and proliferative diabetic 
retinopathy (0.6%)  [39] . In the UK, the overall preva-
lence of any diabetic retinopathy in diabetic patients re-
siding in the English town of Melton Mowbray was 52% 
 [42] . The same study demonstrated that 48% of all pa-
tients with diabetic retinopathy had non-proliferative 
diabetic retinopathy and 4% had proliferative diabetic 
retinopathy  [42] . The same trend was observed in Spain, 
where the figures were 38.9 and 5.8%, respectively  [28] . 
A map of the prevalence of diabetic retinopathy is shown 
in  figure 3 . The incidence of all forms of diabetic reti-
nopathy is shown in  figure 4 . The prevalence of different 
types of diabetic retinopathy in Europe is shown in  ta-
ble 3 .
 Clinical Outcomes and Socio-Economic Impact of 
Diabetic Retinopathy 
 Clinical Outcomes 
 Diabetic eye disease is one of the leading causes of 
blindness in the Western world in the 25- to 65-year age 
group  [76] . The most common cause of blindness in pa-
tients with diabetes is macular oedema  [77] . Morpholog-
ical changes that lead to blindness frequently develop 
without any symptoms and remain unnoticed by pa-
tients. Nevertheless, changes can be detected by medical 
examination and treatment is often successful in preserv-
ing sight. Reduced vision and blindness caused by dia-
betic retinopathy are significantly associated with sex, 
age at the time of examination, age at the time of diagno-
sis, duration of diabetes, type of diabetes treatment, and 
hypertension  [78] . 
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 Natural Progression of Diabetic Retinopathy 
 The ocular effects of diabetes are assumed to progress 
from no retinopathy to background retinopathy and then 
either to proliferative retinopathy, macular oedema, or 
both. Patients with asymptomatic macular oedema may 
develop clinically significant macular oedema that can 
progress to central visual loss; proliferative retinopathy 
may also result in visual loss  [47] . The prevalence of mac-
ular oedema was 1.4% in Badajoz, Spain, and 0.85% in 
Germany  [39, 47] . Early screening and treatment of dia-
betic retinopathy were shown to be cost-effective. 
 Economic Costs of Diabetic Retinopathy 
 Screening and treatment of diabetic eye disorders in the 
USA save USD 3,190 per QALY; this refers to a measure-
ment of outcome that takes into account both the quantity 
and the quality of life provided by health care intervention; 
it is the arithmetic product of life expectancy and quality 
of remaining life years  [79] . The average cost for detecting 
and treating diabetic eye disorders in insulin-dependent 
diabetes mellitus was USD 1,996 per QALY, 2,933 USD for 
those with non-insulin-dependent diabetes mellitus who 
use insulin for glycemic control, and USD 2,993 for those 
with non-insulin-dependent diabetes mellitus who do not 
use insulin for glycemic control. Screening and prevention 
programmes thus lead to substantial savings and are cost-
effective societal health investments  [80] . 
 If proliferative retinopathy is untreated, 50% of pa-
tients with retinal neovascularization will be blind with-
in 5 years; 50% of patients with optic disc neovasculariza-
tion will be blind within 2 years  [81] . Laser photocoagula-
tion performed in the early stages of the disease can lead 
to a 60% reduction in severe visual loss at 2 years  [78] .
 Epidemiology of Glaucoma in Europe 
 Glaucoma can be classified into two broad types: 
open-angle and angle-closure glaucoma, each of which 
can be categorized as primary or secondary  [74] . Sixty-
Table 3. P revalence of different DR types
Type of DR Study
location
Study
design
Sample
size
Year Age Gen-
der
Prev-
alence
Grading criteria Method of
diagnosis
Ref.
No.
Non-proliferative DR UK population- 215 1993 adults both 48% criteria were not well described information from 42
Proliferative DR based survey 4% hospital records
Non-proliferative DR Spain population-
based survey
1,179 1993 adults both 38.90% classification from an early treatment 
diabetic retinopathy study 
from medical rec-
ord of diabetologic 
centers
47
Proliferative DR 5.80%
Non-proliferative DR Germany cross-
sectional
population-
based study
5,596 2002–
2004
≥65
years
both 1.70% recommendation for staging of 
proliferative diabetic retinopathy by 
Prof. Kroll, Marburg
OPHTH during 
general diabetes 
screening program, 
standardized 
39
Proliferative DR 0.60%
Mild DR 0.50%
Mild/moderate DR 8.30% protocols
Minimal DR Europe survey 458 2007 adults both 16.70% National Diabetes Retinal Screening 
Grading System and referral 
recommendations. Save Sight Society of 
New Zealand Inc., 2005
SQ, OPHTH, FI 25
Mild DR 16.70%
Moderate DR 1.30%
Proliferative DR 2.70%
Moderate or worse DR 4%
Proliferative DR Europe multi-
national co-
hort study
29,994 2001
(8.4 years
of follow-
up)
all ages both 36.20% DR classification as described by 
Fukuda [107]: preproliferative 
retinopathy (PR) (B1), early stage (B2)
Advanced stage (B3), end stage of 
proliferative diabetic retinopathy (B4)
Mild to moderate (Al)
Severe simple retinopathy (A2), 
moderate interrupted proliferative 
retinopathy
Severe interrupted proliferative 
retinopathy (A4)
enquiry method,
SQ
16
D R = Diabetic retinopathy; SQ = standard questionnaire, FI = fundus image; OPHTH = ophthalmological examination.
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seven million persons globally, of whom 25 million live 
in Europe, are affected by glaucoma  [82] . It has been es-
timated that 12.3% of the worldwide population and 
21.8% of European adults (including 18% of those over 50 
years of age) have been diagnosed with glaucoma  [32, 35, 
83] . Overall, glaucoma is responsible for 5.2 million cases 
of blindness (15% of global blindness)  [84] . 
 Visual loss in patients with glaucoma is explained by 
progressive damage to optic nerve fibres. According to 
recent epidemiological studies, Germany (14%)  [26] 
shows the highest prevalence of glaucoma in Europe fol-
lowed by the European North of Russia (11.9%)  [29] . The 
lowest prevalence of any type of glaucoma has been reg-
istered in France (3.4%)  [50] and the UK (3.3%)  [85] . A 
map of the prevalence of glaucoma in Europe is shown in 
 figure 5 . 
 A Spanish epidemiological study showed that primary 
open-angle glaucoma [2.1% (99% CI: 1.9–2.3)] was more 
prevalent in men (2.4%) than in women (1.7%)  [48] . A 
cross-sectional study performed in the UK every year 
from 2000 to 2003 estimated that open-angle glaucoma 
and ocular hypertension increased both in men (from 
3.41 to 3.6%) and in women (from 2.96 to 3.12%), but the 
prevalence was always higher in men than in women  [86] . 
 A retrospective longitudinal study performed in 
Southern Germany with 5 years of follow-up and 3,531 
participants showed that the incidence of glaucoma was 
2.37 (95% CI: 1.93–2.81)  [87] . A cross-sectional study 
from the European North of Russia estimated the inci-
dence of glaucoma at a level of 1.3 cases in 1,000 persons 
 [56] . A population-based survey with 647 participants 
aged 60–74 years was performed in Germany in 1999. 
This study showed that the sex-specific incidence of glau-
coma was also higher in men (6.64%) than in women 
(2.96%)  [31] . A map of the incidence of glaucoma in Eu-
rope is shown in  figure 6 .
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 Population projections for the years 2010 and 2020 in-
dicate that open-angle glaucoma will become the most 
prevalent type of glaucoma in Europe, with a prevalence 
of 23.9 and 21.1%, respectively  [88] . Open-angle glaucoma 
accounts for 56.5% of all cases of glaucoma in Russia  [35] . 
On average, this type of glaucoma accounts for 80% of all 
cases of glaucoma and becomes more common with in-
creasing age  [84] . The age- and sex-specific prevalence of 
glaucoma in Europe is shown in  table 4 . The incidence of 
different types of glaucoma in Europe is shown in  table 5 .
 Clinical Outcomes and Socio-Economic Impact of 
Glaucoma 
 Glaucoma is the second most common cause of blind-
ness among the elderly in developed countries  [91] . The 
number of patients with blindness due to glaucoma in 
different countries varies between 5 and 33%  [92] . The 
symptoms of glaucoma are not obvious in its early stages, 
when treatment can be the most beneficial, and aware-
ness about the early signs and symptoms of glaucoma is 
low in many countries  [93] . Conversion of ocular hyper-
tension to glaucoma is associated with such risk factors 
as older age, higher intraocular pressure, larger cup-disc 
ratio, and lower central corneal thickness  [94] .
 A prospective study of medical costs of glaucoma and 
ocular hypertension performed in Italy showed that the 
greater the severity of this disorder, the higher the eco-
nomic losses. The annual average cost per patient was 
EUR 788.7 and rose significantly with disease severity 
from EUR 572 for ocular hypertension, EUR 734.3 for 
glaucoma, and EUR 1,054.9 for advanced glaucoma  [95] . 
A multinational long-term study of direct costs of glau-
coma and disease severity demonstrated a statistically 
significant increasing linear trend (p = 0.018) in direct 
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Table 4. A ge- and sex-specific prevalence of different types of glaucoma
Type of
glaucoma
Study 
location
Study design Sample
size
Year Age Gen-
der
Prevalence
% 
Method of grading Ref. 
No.
OAG Rotterdam, 
Netherlands
population-
based prospective 
cohort
6,781 1990–1999 65–74 both 22.50 special for this study: incident VF loss
presence of a VF defect in at least one eye
on Goldmann perimetry in a participant
from a cohort at risk or the presence of a
defect of at least six continuous points
45
Other types 3.30
OAG Lebanon cross-sectional 
study
298 2007 40 years
of age
and older
both 7.30 criteria were not well described 46
OAG France cross-sectional
study
3,896 2003 Adults 
older than 
18 years
of age
both 61.70 Manual of International Classification of 
Diseases, Injuries, and Causes of Death 
Geneva: Switzerland: World Health 
Organization, 1977 
27
Normal-ten-
sion glaucoma 3.40
ACG 5.50
Early POAG Austria long-term
follow-up study
4,864 2006/8 years 
of follow-up
Adults both 2.9 (2.3–3.5) Terminology and Guidelines for Glaucoma
(ed. 3)
52
POAG suspect 8.5 (7.6–9.4)
POAG Spain cross-sectional 
population-based 
596 2004 Adults male 2.40 POAG: presence of glaucomatous optic
disc + glaucomatous VF changes + intra-
ocular pressure >21 mm Hg1
48
female 1.70
POAG Italy population
based preva-
lence survey
1,034 1997 40 years 
and older
both 2.51 (1.72–3.66) glaucomatous VF defects (sensitivity decrease 
≥6 db in at least one location of the central 
10°, two locations for the central 20° or three 
locations of the central 30°, IOP >20 mm Hg, 
CDR >0.5, difference in CDR >0.2
51
Primary ACG 0.97 (0.53–1.77)
POAG Austria cohort study 853 2007/5 years ≤50 both 0.7 (0.3–1.9) Terminology and Guidelines for Glaucoma
(ed. 3)
89
≥60 6.9 (1.7–24)
OAG Thessaloniki,
Greece
cross-sectional, 
population
based study
2,554 1999 >60 male 3.8 specific study definition: presents of both 
glaucomatous optic nerve and confirmed 
glaucomatous VF defects
18
female 3.7
60–64 both 2.6
65–69 2.6
70–74 4.8
75–76 5.3
>80 4.3
O AG = Open-angle glaucoma; POAG = primary open-angle glaucoma; ACG = angle-closure glaucoma; SQ = Standard Questionnaire; OPHTH = ophthalmo-
logical examination; VF = visual field. 1 Not obligatory diagnostic criterion.
Table 5. I ncidence of different types of glaucoma
Type of
glaucoma
Study
location
Study design Sample
size 
Year Age
years
Sex Incidence Method of diagnosis Ref. 
No.
POAG Peterborough,
UK
calculation of the local 
prevalence and inci-
dence of POAG using 
clinical audit data
164,000 2000 60–64 both 33.57 (6.92–98.05) definition of glaucoma by Gupta
and Weinreb [89]
54
65–69 122.24 (58.68–224.94)
70–74 136.29 (62.43–258.97)
Austria cohort study 853 2007/5 years 
follow-up
50  both 0.7% (0.3–1.9%) Terminology and Guidelines
for Glaucoma (ed. 3)
90
60 6.9% (1.7–24%)
Glaucoma,
all types
Germany retrospective longi-
tudinal study
3,531 1994–1998 60–79 both 2.37 (1.93–2.81) definition of the European Glauco-
ma Society including definition of 
incidence of blindness due to glauco-
ma-BCVA ≤1/50 in the better eye, 
and VF ≤5° 
87
OP HTH = Ophthalmological examination; BCVA = best-corrected visual acuity; VF = visual field.
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cost as glaucoma severity worsened. The direct costs of 
treatment increased from EUR 455 per person-year for 
stage 0 to EUR 969 per person-year for stage 4 disease, 
accounting for EUR 86 for each incremental step  [96] . 
These facts stress the importance of early screening, di-
agnostics and treatment of glaucoma. Several epidemio-
logical studies have shown that at least half of the pa-
tients with glaucoma remain undiagnosed  [97] , whereas 
more than half of those who are undergoing treatment 
do not have the disease  [98] . More than half of patients 
who were newly diagnosed with glaucoma during 
screening have seen an ophthalmologist before, but 
glaucoma remained undiagnosed  [99] . Since there are 
no early warning symptoms, it was recommended that 
all adults over 50 years of age be tested for glaucoma ev-
ery 2 years  [95] . Glaucoma has received very little atten-
tion from health economists  [100] . This can mostly be 
explained by the lack of major parameters needed for 
cost-effectiveness analyses such as: limited utility data 
mostly based on cross-sectional pilot studies, no stan-
dards for collation and report of cost data in glaucoma 
care, and low sample size, special inclusion and exclu-
sion criteria used in RCTs, protocol-driven costs are lim-
iting the application of RCT results to the general popu-
lation  [100] .
 Lowering of intraocular blood pressure is important 
for the treatment of glaucoma. This can be achieved by 
using topical and/or oral medications, laser surgery, con-
ventional surgery, or a combination of these therapies 
 [101] . Current health economics studies on glaucoma 
treatment mostly focus on direct costs of glaucoma drugs, 
and therefore provide only one component of real glau-
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coma treatment costs  [100, 102, 103] . The main issue that 
limits this research in the area of glaucoma treatment is 
absence of a reliable, transparent and validated long-term 
effectiveness measure  [100] .
 Discussion 
 Europe is a continent characterized by high regional 
variations  [2] . The epidemiological rates of visual impair-
ment vary significantly between Western, Central and 
Eastern Europe and require further review. Moreover, 
longer life expectancies in developed European countries 
will increase the prevalence and incidence of age-related 
eye disorders  [32] . Data collection in Europe is currently 
fragmented due to diverse legal constraints and privacy 
protection guidelines, which make it difficult to collect 
patient-related data on a single central server. Further-
more, there is little data exchange among European 
health care systems, governments and research institu-
tions. Most epidemiological research to date has been 
performed on the national level; only very few Europe-
wide studies exist. 
 AMD is the third most frequent cause of blindness 
globally. It is more frequent in women than in men and 
tends to increase with age, with a sharper increase in 
women than men; this can probably be explained by the 
longer life expectancy of women  [13] . The incidence of 
AMD was also found to increase with age  [30] ; it was not 
significantly different between men and women  [31] . On 
average, Western European, such as France  [27] and Ger-
many  [26] , tend to have a higher prevalence of AMD than 
Eastern European countries, including Russia  [29] and 
Bulgaria  [2] . These differences could be explained by the 
longer life-expectancy of the Western European popula-
tion in comparison with the population in Eastern Eu-
rope  [104] . This leads to more individuals in Western Eu-
rope surviving until they are diagnosed with AMD in 
comparison with Eastern Europe. Neovascular AMD 
was shown to be more prevalent in the UK, although 
these differences were not statistically significant  [28] . It 
is hard to differentiate these two types at later disease 
stages. Furthermore, patients with geographic AMD tend 
to visit an ophthalmologist earlier than those with neo-
vascular AMD  [28] , which can influence the result of ep-
idemiological data comparison. Cigarette smoking, low 
dietary intake of vitamin E and zinc, increased exposure 
to sunlight and concomitant cardiovascular disease are 
the main risk factors of AMD  [12] that must be tackled 
during intervention and prevention programmes. Fur-
ther studies must be done to clarify the source of differ-
ences in AMD prevalence between Western and Eastern 
Europe. All epidemiological studies on the prevalence 
and incidence of AMD used the same International Clas-
sification and Grading System for AMD and ARMD 
 [105] ; despite this fact, some of these studies used slightly 
different age group definitions, which complicated the 
comparison of age-specific prevalence and incidence be-
tween studies. Some studies differentiated AMD by dis-
ease stage (early/late) and type (geographic/neovascular), 
whereas others only defined AMD type.
 The natural progression of AMD to geographic atro-
phy takes an average of 6.6 years (range 4–11)  [64] . How-
ever, early screening and identification of individuals 
with a higher risk of AMD together with nutritional and 
new preventive strategies can slow down this progression. 
There is an ongoing debate on off-label use of bevacizu-
mab for treatment of wet AMD. As discussed in a Novar-
tis-sponsored literature review on this topic, the issue of 
off-label bevacitzumab use still remains controversial 
due to the absence of high-quality and robust RCT data 
for the comparative efficacy and long-term safety of this 
treatment approach in comparison with established ones, 
such as ranibizumab treatment  [73] .
 According to the literature reviewed in this study, dia-
betic retinopathy affects 3  [32] to 4.1%  [33] of Europeans. 
Recent epidemiological studies have shown that France 
 [46] and Germany  [39] show the highest prevalence of 
diabetic retinopathy in Europe. Its incidence was quite 
similar among European countries, being highest in the 
UK and closely followed by Switzerland, Poland and Ger-
many  [34] . This trend can be explained by the higher 
prevalence of lifestyle risk factors such as systemic hyper-
tension, hyperglycaemia, hypercholesterolaemia, ciga-
rette smoking, and diabetic nephropathy in older Euro-
peans  [76] . The incidence of diabetic retinopathy was 
shown to be higher among men than among women in 
the 60- to 74-year age range  [31] . Furthermore, non-pro-
liferative diabetic retinopathy was the most frequent type 
in most European countries  [42] . Studies on the epidemi-
ology of diabetic retinopathy used different sources for 
diagnostic standards, e.g. Early Treatment Diabetic Reti-
nopathy Study criteria  [106] or the diabetic retinopathy 
classification described by Fukuda  [107] . Nevertheless, 
the diagnostic criteria appeared to be quite similar, en-
abling the comparison of results. Several studies graded 
diabetic retinopathy using stages (minimal, mild and 
moderate). 
 Diabetic retinopathy is difficult to identify in early 
screening when treatment can be most effective. Symp-
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toms appear only at the stage of proliferative retinopathy 
or macular oedema. Patients diagnosed with prolifera-
tive retinopathy have a very poor prognosis with respect 
to visual function. However, early screening and preven-
tion programmes have been shown to be cost-effective, 
and laser coagulation, performed early enough, can sta-
bilize the progression of the disease and prevent blind-
ness. 
 Glaucoma is one of the leading causes of blindness 
both in Europe and worldwide  [84] . The prevalence of 
glaucoma ranged widely across Europe; it was highest in 
Germany  [26] and the European North of Russia  [29] and 
lowest in France  [50] and the UK  [85] . This could be due 
to the higher frequency of risk factors such as high intra-
ocular pressure, age, various forms of vascular pathology 
(diabetes, systemic hypotension/hypertension, vasospas-
tic syndrome), myopia, cigarette smoking and alcohol 
consumption in the former countries  [108] . Spanish data 
showed that open-angle glaucoma is more prevalent in 
men than in women, but increases in frequency in both 
sexes over time  [48] . The incidence of glaucoma was high-
er in Germany  [87] than in the European North of Russia 
 [56] . Sex-specific glaucoma incidence was also higher in 
men than in women  [31] . A population projection study 
indicated that open-angle glaucoma will be the most fre-
quent type in 2010 and 2020, and recent studies also show 
that this type accounts for 80% of all glaucoma cases  [88] . 
Epidemiologic studies on glaucoma often lacked gener-
ally approved diagnostic criteria and used different diag-
nostic tests that made it difficult to compare available 
data.
 Early diagnosis of glaucoma is difficult because the 
disease is asymptomatic in its early stages, when treat-
ment is most beneficial, and it can progress unnoticed. 
High intraocular pressure is a condition which, if not 
identified in its early stages, will lead to glaucoma. The 
overall estimate of the prevalence of ocular hypertension 
in a Spanish cross-sectional study was 1.7% (CI 99%: 1.6–
1.8). Prevalence rates of ocular hypertension did not sig-
nificantly differ between men (1.8%) and women (1.6%) 
 [48] . The prevalence estimate was highest in the age range 
40–49 (2.6%), lowest in the age range 50–59 (0.9%), and 
homogeneous among those over 60 (1.6–1.7%)  [48] . Over-
all, the prevalence of ocular hypertension was higher in 
Austria than in Spain. Cross-sectional studies from 
France  [49, 50] used different diagnostic and research ap-
proaches and were not comparable with other studies. 
Despite the importance of data on such high-risk condi-
tions as high intraocular pressure and ocular hyperten-
sion, our literature search found only 5 epidemiological 
studies on the subject. This indicates the importance of 
much more extensive research to better estimate the 
prevalence and incidence of these diseases in Europe. The 
prevalence of high intraocular pressure and ocular hy-
pertension in Europe is shown in  table 6 . Studies indicate 
that knowledge about glaucoma was low in the general 
population of many countries. Glaucoma leads to high 
societal costs, which are strongly correlated with disease 
Table 6. P revalence of high intraocular pressure (IOP) and ocular hypertension (OHT) in Europe
Disease Study 
location
Study
design
Sample
size 
Year Age Sex Prevalence
 % 
Inci-
dence
Grading methods Methods of diagnosis Ref. 
No.
High
IOP
Italy population-based 
prevalence survey
1,034 1997 ≥40 both 6
(4.71–7.61)
glaucomatous VF defects 
(sensitivity decrease ≥6 db in
at least 1 location of the central 
10º, 2 locations for the central 
20º or 3 locations of the central 
30º, IOP >20 mm Hg, CDR 
>0.5, difference in CDR >0.2
standardized initial 
examination + definite 
examination with VF 
testing
51
OHT Segovia,
Spain
cross-sectional 
population-based 
study
596 2004 >60 both
men
women
1.7
1.80
1.60
0.9
0.9
0.9
diagnostic criteria were
specific to this study OHT IOP 
>21 mm Hg, no changes in 
optic disc or VF
OPHTH 48
France cross-sectional 
study
3,896 2003 >18 both 29.50 Terminology and Guidelines
for Glaucoma (ed. 3)
ophthalmological 
reports
49, 
50
Austria long-term
follow-up study 
4,864 2006 adults, no 
children
both 2.2
(1.7–2.7)
Terminology and Guidelines
for Glaucoma (ed. 3)
OPHTH 52
VF = Visual field; OPHTH = ophthalmological examination.
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severity. Because glaucoma normally does not have warn-
ing symptoms, every person older than 50 years of age 
should be tested for high intraocular pressure. 
 Previous literature reviews related to the epidemiology 
of major eye diseases have focused mostly on the inci-
dence of blindness and its causes  [109] or on a specific 
disease within a specific country or geographic region, 
e.g. AMD  [12–14] , diabetic retinopathy  [15–17] , glaucoma 
 [19, 36] , or cataract  [110] . One of the most comprehensive 
and recent literature reviews was conducted in 2002 
within the WHO Programme for the Prevention of Blind-
ness and Deafness and contained data on the prevalence 
of blindness and low vision in WHO regions as well as on 
the percentage of total blindness by cause  [109] . Never-
theless, data on the prevalence and incidence of major eye 
diseases were not presented. Furthermore, data on Eu-
rope were significantly lacking in comparison with other 
WHO regions, and a comparison of different countries 
was not included. The study included results from 25 Eu-
ropean population-based studies published between 1982 
and 2000. Kocur and Resnikoff  [2]  reviewed 5 European 
studies on major eye diseases published from 1970 to 
1998. While they summarized the impact of these dis-
eases on visual impairment within each country, they 
failed to compare epidemiological data among the stud-
ies. 
 The present study compared data from (to the best of 
the authors’ knowledge) all recent European studies con-
cerning the incidence and prevalence of AMD, diabetic 
retinopathy and glaucoma over a period of 18 years from 
1990 to 2008. An overview and comparison of overall and 
specific prevalence and incidence estimates of major eye 
diseases in Europe are presented, and the natural pro-
gression, the economic impact, and methods of treatment 
discussed.
 The literature search included all papers relevant to 
the epidemiology of major eye diseases leading to blind-
ness in Europe without restriction to any specific ethnic-
ity. The available publications did not adequately report 
on the epidemiology of these diseases for non-Caucasian 
populations. Therefore, the scope of the paper was lim-
ited in order to perform a comprehensive analysis of 
available studies on individuals of Caucasian origin, 
which represent the majority of the European population. 
The issue of ethnic differences is quite complicated and, 
unfortunately, rarely described in the literature. While 
we were not able to include summary information here, 
we welcome future research on the topic.
 Some caution is advisable when comparing different 
epidemiological studies, especially from different Euro-
pean countries since such studies often use different di-
agnostic criteria, possibly with different age group defini-
tions and diagnostic methods. This is particularly true of 
a review of the literature on glaucoma epidemiology since 
there are no well-established, commonly accepted crite-
ria in Europe for its diagnosis. We attempted to minimize 
this limitation by using very specific and strict inclusion 
criteria. The studies reported in this paper used similar 
diagnostic procedures and approaches. Where differenc-
es remained, we have clarified this to ensure the reliabil-
ity of conclusions derived from this systematic literature 
review.
 Overall, the present study showed that, despite the 
large number of epidemiological studies of major eye dis-
eases performed worldwide, accurate data are still largely 
lacking for Europe. This study highlighted the impor-
tance of undertaking multicentre, population-based 
studies of major eye diseases leading to blindness in Eu-
rope. Generally approved diagnostic criteria and gold 
standard screening diagnostic procedures are required to 
make results of such studies comparable.
 The results of the present systematic literature meta-
analysis will help policy makers, researchers, patient or-
ganizations and pharmaceutical companies to better un-
derstand the epidemiology of major eye diseases in Eu-
rope. It is the authors’ hope that these results will also lead 
to the establishment of a common set of preventive mea-
sures based on solid epidemiological data and will make 
it possible to monitor the effects of such prevention and 
intervention.
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